Statin Use and Risk of Prostate Cancer in a Population of Men Who Underwent Biopsy
|
|
- Collin Ward
- 5 years ago
- Views:
Transcription
1 Statin Use and Risk of Prostate Cancer in a Population of Men Who Underwent Biopsy Nelly Tan,* Eric A. Klein, Jianbo Li, Ayman S. Moussa and J. Stephen Jones From the Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio Abbreviations and Acronyms BMI body mass index DRE digital rectal examination GS Gleason score PB prostate biopsy PC prostate cancer PSA prostate specific antigen Submitted for publication October 21, Study received institutional review board approval. * Correspondence: Department of Urology, Yale-New Haven Hospital, New Haven, Connecticut ( nelly.tan@gmail.com). Financial interest and/or other relationship with Pfizer, Cook, Abbott, Endocare and GTx. For another article on a related topic see page 302. Purpose: We determined the association between statin use and prostate cancer in men who underwent prostate biopsy. Materials and Methods: We performed a retrospective cohort study of men who underwent prostate biopsy from 2000 to 2007 at Cleveland Clinic. Statin use was determined using outpatient pharmacy records, and clinical and pathological outcomes were obtained. Multivariate logistic regression analysis to determine the effects of statins (and duration of use) was performed after adjusting for age, body mass index, African-American race, number of cores taken and prostate volume. Results: We analyzed data from 4,204 patients, and we identified 3,182 (75.7%) not on statins and 1,022 on statins. Men diagnosed with prostate cancer on statins compared to those not taking statins were less likely to have digital rectal examination positivity (5.3% vs 8.9%, OR 0.7, p 0.01), Gleason score 7 or greater prostate cancer (61.4% vs 72.4%, OR 0.78, p 0.02) and high volume prostate cancer (27.2 vs 31.4, p 0.01). Moreover statin users had lower prostate specific antigen compared to nonstatin users (5.13 vs 5.98, p 0.03). Multivariate analysis adjusted risk ratios for prostate cancer diagnosis, high grade prostate cancer (Gleason score 7 or greater) and 3 or more cores positive in statin users were 0.92 (95% CI ), 0.76 (95% CI ) and 0.86 (95% CI ) and only high grade prostate cancer persisted with length of use. Conclusions: Statin use was associated with a decreased risk of prostate cancer, less frequent high grade prostate cancer and lower volume of prostate cancer, suggesting that statin use has a protective effect against prostate cancer. Key Words: prostatic neoplasms, hydroxymethylglutaryl-coa reductase inhibitors PROSTATE cancer is the second most common cancer in the United States. Efforts to prevent this cancer remain important because screening has been shown to have only a modest effect on reducing mortality, 1,2 and while effective in curing early stage tumors, definitive therapy is associated with significant morbidity. Statins are a class of cholesterol lowering drugs that work by inhibiting 3-hydroxy-3-methylglutaryl coenzyme-a reductase and have recently demonstrated a chemopreventive effect in vitro on PC cell cultures. 3,4 There is controversy regarding the effects of statins on the overall risk reduction of PC, with some studies suggesting no effect while others suggest significant risk reduction, especially in advanced stage tumors. 5 7 However, there are minimal published data on a population of men being screened for prostate cancer and outcomes such as tumor volume have not been explored. We performed a retrospective cohort study to investi /11/ /0 Vol. 186, 86-90, July 2011 THE JOURNAL OF UROLOGY Printed in U.S.A by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. DOI: /j.juro
2 STATIN USE AND RISK OF PROSTATE CANCER 87 gate the association of statin use, and PC risk, high grade PC and PC volume in men who underwent prostate biopsy. MATERIALS AND METHODS Study Setting We performed a retrospective cohort study of patients who underwent prostate biopsy at a tertiary medical center, Cleveland Clinic. We used an institutional review board approved database of patients who underwent PB. All patients included in the study had a urologist perform the initial prostate biopsy from 2000 to Patients were excluded from study if we did not have complete pathological information. Study Subjects The population of patients evaluated at Cleveland Clinic includes self-referrals and provider-to-provider referrals. We identified 4,733 patients who underwent consecutive PB for increased PSA and/or abnormal DRE. Of the 4,733 men 529 (11.1%) were excluded from study because of incomplete pathological data (ie tumor grade information). We analyzed the remaining 4,204 patients, and we identified 3,182 (75.7%) patients not on statins and 1,022 who used statins. Exposure Statin use was evaluated in all patients who had electronic prescribing records, which were available for all patients in the study. Patients taking medications containing lovastatin, atorvastatin, cerivastatin, rosuvastatin, simvastatin, fluvastatin and/or pravastatin were considered statin users. Men were categorized as statin users if they were taking statins before undergoing PB. Those who did not have statin use information before biopsy were considered nonusers. The duration of statin use was determined by taking the difference between the start date of statin use and the date of PB. Statin use duration was categorized as 0 to 5 years and greater than 5-year use before PB was performed. This breakdown in years was used because a previous study suggested that a protective effect of statins was seen in men using statins for more than 5 years. 8 Clinical Characteristics Clinical variables collected were patient age, race (African-American vs all other), DRE status (positive or negative), BMI, serum PSA and prostate volume. Prostate volume was measured by transrectal ultrasound or by surgical prostatectomy specimen weight when transrectal ultrasound estimated volume was unavailable, which was the case in 20% of the patients. BMI was divided into 3 groups per National Institutes of Health obesity guidelines of less than 25, 25 to 30 and greater than 30 kg/m 2. 9 Prostate Cancer Ascertainment Pathological information collected from the pathology report of our electronic medical records included biopsy Gleason sum, number of cores obtained and number of cores positive. Biopsy specimens were reviewed by dedicated genitourinary pathologists according to a previously described protocol. 10 Indications for biopsy and prostate biopsy technique were published previously. 11 Tumor volume was assessed by the 2 measures of 3 or more cores positive for PC (considered to have high volume PC) and the percent of cores positive (number of cores positive/total cores taken). 12,13 Statistical Analysis Data were presented as means with standard deviations and medians with interquartile ranges. Group comparisons were done using the Wilcoxon rank sum test for continuous variables and the chi-square test for categorical variables. Multivariate logistic regression analysis was used to assess the effect of statin use and the duration of statin use on PC incidence, high grade PC and PC volume. Potential confounding factors such as age, BMI, African-American race, DRE positivity, prostate volume and number of cores surveyed were used as covariates in the modeling. The resulting odds ratios and CIs were converted to risk ratios for easy interpretation. A correlation test was used for the relationship between GS and duration of statin use. All analyses were done using the statistical software package R (R Development Core Team, and statistics were considered significant at RESULTS We analyzed 4,204 patients including 3,182 (75.7%) not on statins and 1,022 using statins. Patient clinical and pathological data are presented in table 1. Of the statin users 55.2% were diagnosed with PC, whereas 57.8% of patients not on statins had PC (p 0.15). The mean age of men with PC who were not on statin and who were on statin was 63.5 and 65.7 (p 0.01), respectively. Compared to patients not taking statins, men diagnosed with PC who were on statins were less likely to have DRE positivity (5.3 vs 8.9, p 0.01), GS 7 or greater PC (OR 0.78, p 0.02) and high volume prostate cancer (27.2 vs 31.4, p 0.01). Median PSA was lower in men being screened for PC who were on statins compared to those who were not on statins (5.13 vs 5.98, p 0.03). However, there was no difference in median PSA for men diagnosed with PC (6.44 vs 7.03, p 0.94). Multivariate logistic regression analysis demonstrated sustained protective associations between statin use and prostate cancer risk. After adjusting for age, BMI, African-American race, DRE, prostate volume and number of cores surveyed, patients on statins at any time were less likely to have prostate cancer (RR 0.92, 95% CI ) and high grade prostate cancer (RR 0.76, 95% CI ). Statin users also had a lower incidence of high volume (3 or more cores positive) PC (RR 0.86, 95% CI ). Moreover greater than 5 years of statin use predicted a lower rate of high grade PC (RR 0.75, 95% CI , table 2). The cumulative incidence of prostate cancer, high grade PC and high
3 88 STATIN USE AND RISK OF PROSTATE CANCER Table 1. Patient clinical and pathological data Statin Nonusers Statin Users Chi-Square p Value No. underwent PB (%) 3,182 (75.7) 1,022 (24.3) No. no PC (%) 1,340 (42.1) 457 (44.7) 0.15 No. GS 6 or greater (%) 1,842 (57.8) 565 (55.2) Mean age of men with PC (IQR) 63.5 (57 69) 65.7 (60 71) 0.01 No. African-American with PC (%) 370 (11.6) 157 (15.4) 0.01 No. DRE pos with PC (%) 275 (8.9) 54 (5.3) 0.01 No. kg/m 2 BMI with PC (%): Less than (23.6) 165 (18.3) ,026 (49.2) 432 (47.9) Greater than (27.2) 305 (33.8) Median PSA in all men (IQR) 5.98 ( ) 5.13 ( ) 0.01 Median PSA in men with PC (IQR) 6.44 ( ) 7.03 ( ) 0.94 No. pathological Gleason sum (%): (27.6) 218 (38.6) (42.5) 186 (32.9) (15.4) 77 (13.6) 8 or Higher 268 (14.5) 84 (14.9) No. cores obtained in PB (IQR) 11.6 (10 12) 12.6 (10 12) 0.01 No. pos cores (IQR) 2.0 (0 3) 1.9 (0 3) 0.36 No. 3 or more cores pos (%) 976 (31.4) 274 (27.2) 0.01 Mean cc prostate vol in men with PC (IQR) 48.1 (33 57) 46.0 ( ) 0.01 volume PC was lower in statin users as patient age increased (see figure). DISCUSSION In this cohort of patients the results indicate that statin users who underwent biopsy had a lower rate of DRE positivity, lower PSA, smaller prostate, as well as a lower rate of high grade and lower volume PC compared to nonusers who underwent biopsy. In addition, on multivariate analysis longer duration of statin therapy was associated with an overall lower rate of high grade PC. The lower risk of PC may be associated with antineoplastic effects of statins beyond the PSA suppression effects observed in published studies Since increased PSA is a common indication for prostate biopsy, suppression of PSA in statin users may complicate PC detection in men on statins. Consistent with other studies the median PSA in our patient population was 14% lower in statin users who underwent biopsy. However, in patients diagnosed with PC there was no difference in PSA, suggesting PSA lowering effects of statins in benign tissue but not in malignant tissues. Moreover since PSA was similar in the statin and control cohorts of men diagnosed with PC, one would presume a similar breakdown of low, moderate and high grade PC. Instead we found that statin users had a lower rate of GS 7 or greater PC, which suggests an antineoplastic effect of statin use. One mechanism by which statins could induce an antineoplastic effect is via apoptosis of prostate cancer cells, which was demonstrated in in vitro studies. 17,18 Some have suggested that the statin user population may inherently undergo increased screening, but published studies have shown the reduced risk of PC in statin users after adjusting for PSA testing. 6,15 Murtola et al compared statin users and nonusers undergoing screening for prostate cancer, and found that the overall incidence of PC was lower among statin users when bias due to differential PSA testing was eliminated. 15 Thus, more evidence is beginning to suggest that statins not only have PSA lowering effects, but they also may possess antineoplastic potential. Table 2. Risk ratio of overall incidence of PC, high grade PC and PC volume based on length of statin use Underwent PB No PC PC (GS 6 or greater) High Grade PC (GS 7 or greater) 3 or More Cores Pos No. no statin use (%) 3,182 1,340 (42.1) 1,842 (57.8) 1,334 (72.4) 976 (52.9) No. ever statin use (%): 1, (44.7) 565 (55.2) 347 (61.4) 274 (48.4) 0 5 Yrs (45.2) 495 (54.7) 305 (61.6) 241 (48.6) Greater than 5 yrs (40.6) 70 (59.3) 42 (60.0) 33 (47.1) RR (95% CI) ever statin use: Ref Ref 0.92 ( ) 0.76 ( ) 0.86 ( ) 0 5 Yrs Ref Ref 0.92 ( ) 0.78 ( ) 0.80 ( ) Greater than 5 yrs Ref Ref 0.95 ( ) 0.72 ( ) 0.81 ( )
4 STATIN USE AND RISK OF PROSTATE CANCER 89 Cumulative incidence of overall prostate cancer (A), high grade prostate cancer (B) and 3 or more cores positive (C) The effect of statins on the incidence of PC has been controversial in published studies. Reported study results have ranged from increased incidence of PC, 5 to no effect on PC incidence, 19 to a decrease in overall incidence, 20 to a decrease only in high grade/advanced PC 6,21,22 in statin users. Friis et al conducted a population based cohort study, and found no difference in PC between statin users and nonusers. 19 In contrast, Jacobs et al reported a reduced risk of only advanced PC in statin users (rate ratio 0.60, 95% CI ), 6 later supported by additional studies. 5,21,22 Other studies have demonstrated a reduced risk of PC 8,20,23 and high grade PC 6 in statin users. There is no consensus on the exact effect of statin use on PC in these population based cohort studies. All patients in our study underwent biopsy because of positive DRE or increased PSA and, thus, if statins have protective effects against PC as demonstrated in our study for overall PC and for high grade PC, those undergoing PB may be the group likely to show the association. Our results also demonstrate that statin use was associated with a lower volume of PC. Similar findings of lower prostate volume have been reported in men taking statins. Loeb et al studied prostatectomy specimens and found that men on statins had a lower percentage and lower volume of cancer. 24 Lower PC volume and lower rate of high grade cancers in men on statins may be explained by the cholesterol lowering effects of statins. Freeman and Solomon proposed a mechanism by which cholesterol could promote PC development, 25 in that high serum cholesterol contributes to the lipid raft component of the plasma membrane, which may stimulate signaling pathways that promote progression to hormone refractory disease. A nested case-control study demonstrated that a low plasma level was associated with a lower risk of high grade disease. 26 An additional study evaluated the association between serum cholesterol and prostate cancer, particularly high grade disease, in the placebo arm of the Prostate Cancer Prevention Trial. The study showed that men with normal serum cholesterol had a statistically significant lower risk of GS 8 to 10 PC (OR 0.41, 95% CI ), especially when the disease was also organ confined (OR 0.32, 95% CI ). 27 The protective effects of statins have been further suggested in several studies that report improved oncologic outcomes after treatment for PC. Gutt et al retrospectively analyzed 691 men treated with curative intent radiotherapy, and found that statin use was associated with improved freedom from biochemical failure and relapse-free survival. 28 Similar improved outcomes were also observed after prostatectomy. Hamilton et al examined 1,319 patients treated with radical prostatectomy and found that statin users had a dose dependent lower risk of PSA recurrence postoperatively. 29 In addition to potentially improved pretreatment effects of statins, these studies also purport additional benefits, specifically in posttreatment outcomes. There are a number of limitations to our study. We did not have information on certain potential confounders including comorbidities such as diabetes and coronary artery disease nor did we have information for medications considered to affect PC risk, such as 5 -reductase inhibitors, aspirin and antidiabetic use. In addition, there is selection bias. Since we have information for men who underwent biopsy, we cannot apply our results to the men who did not undergo biopsy. Our database is also from 1 tertiary care facility center. Thus, referral patterns and institutional practices may not be generalizable to the larger population. We do not have a number of PSA testing data for our patients and, thus, we cannot control for screening differences between the
5 90 STATIN USE AND RISK OF PROSTATE CANCER 2 populations. Finally, this is a retrospective study and so we cannot provide a causal relationship between statin use and risk of PC. Despite these limitations, this is the largest study published to our knowledge to show the effects of statins on PC in a population of men who underwent PB. This study is also the first to demonstrate statin effects on prostate cancer volume in a population of men before treatment. Furthermore, the lower prostate volume in statin users suggests the possibility that statins could prevent the development of benign prostatic hyperplasia. Additionally, the multivariate analysis of this study was rigorous, and controlled for more potential risk factors, confounders, than most published studies, including prostate volume, number of cores taken, BMI, DRE positivity, race and age. CONCLUSIONS This study provides evidence that patients screened for PC who use statins are less likely to have cancer detected at the time of initial biopsy, less likely to have moderate to high grade PC and more likely to have lower PC volume compared to nonstatin users. ACKNOWLEDGMENTS Kirsten I. Fishler and Zen Vuong provided critical review of the manuscript. REFERENCES 1. Andriole GL, Crawford ED, Grubb RL 3rd et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: Grubb RL 3rd, Pinsky PF, Greenlee RT et al: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102: Wong WW, Dimitroulakos J, Minden MD et al: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumorspecific apoptosis. Leukemia 2002; 16: Hoque A, Chen H and Xu XC: Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008; 17: Agalliu I, Salinas CA, Hansten PD et al: Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: Jacobs EJ, Rodriguez C, Bain EB et al: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: Murtola TJ, Tammela TL, Lahtela J et al: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: Flick ED, Habel LA, Chan KA et al: Statin use and risk of prostate cancer in the California Men s Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults The Evidence Report. National Institutes of Health. Obes Res, suppl., 1998; 6: 51S. 10. Epstein JI, Allsbrook WC Jr, Amin MB et al: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: Tan N, Lane BR, Li J et al: Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. J Urol 2008; 180: Freedland SJ, Csathy GS, Dorey F et al: Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002; 167: Epstein JI, Walsh PC, Carmichael M et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: Hamilton RJ, Goldberg KC, Platz EA et al: The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: Murtola TJ, Tammela TL, Määttänen L et al: Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010; 127: Krane LS, Kaul SA, Stricker HJ et al: Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183: Lee SJ, Ha MJ, Lee J et al: Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(waf1/cip1) in human prostate carcinoma cells. J Biol Chem 1998; 273: Park C, Lee I and Kang WK: Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 2001; 22: Friis S, Poulsen AH, Johnsen SP et al: Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: Breau RH, Karnes RJ, Jacobson DJ et al: The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol 2010; 184: Murtola TJ, Pennanen P, Syvala H et al: Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 2009; 69: Platz EA, Leitzmann MF, Visvanathan K et al: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: Shannon J, Tewoderos S, Garzotto M et al: Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162: Loeb S, Kan D, Helfand BT et al: Is statin use associated with prostate cancer aggressiveness? BJU Int 2010; 105: Freeman MR and Solomon KR: Cholesterol and prostate cancer. J Cell Biochem 2004; 91: Platz EA, Clinton SK and Giovannucci E: Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 2008; 123: Platz EA, Till C, Goodman PJ et al: Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009; 18: Gutt R, Tonlaar N, Kunnavakkam R et al: Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 28: Hamilton RJ, Banez LL, Aronson WJ et al: Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116: 3389.
NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationJong Chul Jeon, Jaeyoung Park, Sungchan Park, Kyung Hyun Moon, Sang Hyeon Cheon, Sejun Park
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2016 April 34(1): 28-33 http://dx.doi.org/10.5534/wjmh.2016.34.1.28 Original Article Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More information(2015) : 85 (5) ISSN
Boniol, Mathieu and Autier, Philippe and Perrin, Paul and Boyle, Peter (2015) Variation of prostate-specific antigen value in men and risk of high-grade prostate vancer : analysis of the prostate, lung,
More informationStatin Use after Radical Prostatectomy Reduces Biochemical Recurrence in MenWith Prostate Cancer
75:211^217 (2015) Statin Use after Radical Prostatectomy Reduces Biochemical Recurrence in MenWith Prostate Cancer Cheryn Song, 1 Sejun Park, 2 Jinsung Park, 3 Myungsun Shim, 1 Aram Kim, 1 In Gab Jeong,
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationStatin use does not prevent recurrent adenomatous polyp formation in a VA population
Indian J Gastroenterol (2010) 29:106 111 DOI 10.1007/s12664-010-0032-1 ORIGINAL ARTICLE Statin use does not prevent recurrent adenomatous polyp formation in a VA population Nikki Parker-Ray & Jehad Barakat
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationProstate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial
Cancer Causes Control (2016) 27:157 164 DOI 10.1007/s10552-015-0693-2 ORIGINAL PAPER Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening
More informationThe Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma
The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma Robert J. Hamilton, Daniel Morilla, Fernando Cabrera, Michael Leapman, Ling Y. Chen, Melanie Bernstein,
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 21 JULY 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationProstate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive ( ct2) patients
ORIGINAL ARTICLE Vol. 40 (5): 613-619, September - October, 2014 doi: 10.1590/S1677-5538.IBJU.2014.05.05 Prostate volume predicts high grade prostate cancer both in digital rectal examination negative
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationExploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies
Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal
More informationNIH Public Access Author Manuscript Clin Genitourin Cancer. Author manuscript; available in PMC 2015 October 01.
NIH Public Access Author Manuscript Published in final edited form as: Clin Genitourin Cancer. 2014 October ; 12(5): e181 e187. doi:10.1016/j.clgc.2014.02.008. The Impact of Differing Gleason Scores at
More informationValidation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System
Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2
More informationUntreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes
Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,*
More information1. Introduction. Department of Urology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba , Japan 2
Hindawi Publishing Corporation Prostate Cancer Volume 2011, Article ID 754382, 6 pages doi:10.1155/2011/754382 Clinical Study Development and External Validation of a Nomogram Predicting the Probability
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationOncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh
More informationReducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study
Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Luke Witherspoon MD MSc, Johnathan L. Lau BSc, Rodney H. Breau MD MSc, Christopher
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationOriginal Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17
More informationUpgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy
MOLECULAR AND CLINICAL ONCOLOGY 2: 1145-1149 Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy CAROLINA D'ELIA, MARIA ANGELA CERRUTO, ANTONIO CIOFFI, GIOVANNI NOVELLA,
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationORIGINAL ARTICLE OPEN. AS Parker 1, DD Thiel 2, E Bergstralh 3, RE Carlson 3, LJ Rangel 3, RW Joseph 4, N Diehl 1 and RJ Karnes 5
Prostate Cancer and Prostatic Disease (2013) 16, 352 356 & 2013 Macmillan Publishers Limited All rights reserved 1365-7852/13 www.nature.com/pcan OPEN ORIGINAL ARTICLE Obese men have more advanced and
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationOMPRN Pathology Matters Meeting 2017
OMPRN Pathology Matters Meeting 2017 Pathology of Aggressive Prostate Cancer Intraductal Carcinoma and Cribriform Carcinoma Dr. Michelle Downes, Staff Urologic Pathologist Sunnybrook Health Sciences Centre,
More informationPROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER?
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology AGE AND PATHOLOGY OF PROSTATE CA Vol. 31 (4): 331-337, July - August, 2005 PROSTATE BIOPSY: IS AGE IMPORTANT
More informationPSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine
PSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine Abstract While PSA screening for prostate cancer remains a widely used tool
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationA Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationRegional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan
Original Article Prostate Int 14;2(1):19- http://dx.doi.org/.12954/pi.135 P ROSTATE INTERNATIONAL Regional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationPredictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy
www.kjurology.org DOI:10.4111/kju.2010.51.10.677 Urological Oncology Predictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy Seung Jin
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationStatin use and prostate cancer aggressiveness: results from the population-based North
Statin use and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project Emma H. Allott 1,2, Laura Farnan 2, Susan E. Steck 3, Lenore Arab 4, L.
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationFinasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted. Mary W. Redman, Ph.D. 1. Catherine M. Tangen, Dr.
Finasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted Modeling Approach Mary W. Redman, Ph.D. 1 Catherine M. Tangen, Dr. PH 1 Phyllis J. Goodman, MS 1 Howard Parnes, M.D.
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationApproximately 680,000 men are diagnosed with prostate
Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram E. W. Steyerberg,* M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning and F. H. Schröder From the
More informationNomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
Original Article Prostate Int 2013;1(2):69-75 P R O S T A T E INTERNATIONAL Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationNIH Public Access Author Manuscript J Urol. Author manuscript; available in PMC 2010 May 4.
NIH Public Access Author Manuscript Published in final edited form as: J Urol. 2009 December ; 182(6): 2819 2824. doi:10.1016/j.juro.2009.08.086. Intravesical Prostatic Protrusion in Men in Olmsted County,
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationPSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging
european urology 54 (2008) 1073 1080 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer:
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More information